Helen Hyun Jung Lee

Samyang Biopharm USA, Inc. (“SYBUSA”) was founded in 2018 with the headquarters in One Kendall Square, Cambridge, MA. Playing a vital role as a business hub in the United States, SYBUSA focuses on out-licensing its nucleic acid drug delivery system developed in Samyang Biopharm, a biopharmaceutical business unit in Korea. Over the next few years, SYBUSA will also focus on building partnerships with pharmaceutical companies and co-development joint ventures in the United States.